ALB and metastatic malignant neoplasm: CART was associated with improved clinical outcomes and healthcare costs over paracentesis among hospitalized patients with metastatic cancer, particularly in males, patients with serum albumin ≤ 2.5 g/dL, and those with non‐gastrointestinal cancer.